Schroder Investment Management Group Seres Therapeutics, Inc. Transaction History

Schroder Investment Management Group

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$5.46 - $22.6 $537,438 - $2.22 Million	-98,432 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$18.46 - $24.36 $63,188 - $83,384	3,423 Added 3.6%	98,432 $2.35 Million
Q1 2021 May 17, 2021	BUY	$17.66 - $28.92 $78,357 - $128,318	4,437 Added 4.9%	95,009 $1.96 Million
Q4 2020 Feb 16, 2021	SELL	$23.25 - $37.73 $575,693 - $934,232	-24,761 Reduced 21.47%	90,572 $2.22 Million
Q3 2020 Nov 13, 2020	BUY	$3.74 - $28.74 $31,053 - $238,628	8,303 Added 7.76%	115,333 $3.19 Million
Q2 2020 Aug 13, 2020	BUY	$3.04 - $6.2 $55,863 - $113,931	18,376 Added 20.73%	107,030 $509,000
Q2 2019 Aug 08, 2019	SELL	$2.28 - $7.35 $225,273 - $726,209	-98,804 Reduced 52.71%	88,654 $285,000
Q1 2019 May 14, 2019	BUY	$4.83 - $7.21 $205,680 - $307,030	42,584 Added 29.39%	187,458 $1.29 Million
Q4 2018 Feb 14, 2019	BUY	$4.52 - $8.88 $43,880 - $86,207	9,708 Added 7.18%	144,874 $655,000
Q2 2018 Aug 13, 2018	BUY	$6.91 - $9.55 $478,206 - $660,907	69,205 Added 104.92%	135,166 $1.24 Million
Q3 2017 Nov 09, 2017	BUY	$12.81 - $16.85 $844,960 - $1.11 Million	65,961	65,961 $1.09 Million

46.3M

119K

466K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $118M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

Stay updated on Schroder Investment Management Group with notifications on news.